Microdosing GLP 1 agonistsusing doses below FDA approved levels for T2D or obesityis rapidly gaining traction as an off label strategy to improve tolerability, tailor titration, and manage costs. Dan T. At the beginning of this year, Medi Cal cut all coverage for GLP 1 medication for obesity treatment. Very disappointing news. But we must remember that we have other effective treatment options that we Anthem TLC Regional Meeting FY27 Renewal The Guide for Malpractice Insurance for Weight Loss Specialty Practices Cunningham Group